Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04864054
Other study ID # ETUS20GPC3AR124
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date March 11, 2022
Est. completion date December 31, 2026

Study information

Verified date May 2024
Source Eureka Therapeutics Inc.
Contact Teresa Klask, MBA
Phone 925-949-9314
Email Teresa.Klask@eurekainc.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, dose escalation, multi-center, Phase I/II clinical trial aimed at assessing the safety and preliminary efficacy of an investigational ARTEMIS® ECT204 T-cell therapy. The trial is suitable for adult subjects (≥ 18 years of age) diagnosed with GPC3-positive HCC, who have failed or not tolerated at least two (2) different anti-HCC systemic agents. Phase I has concluded and a Recommended Phase II Dose (RP2D) has been determined. We are now conducting Phase II to further confirm the safety profile of ECT204 and evaluate its efficacy.


Description:

This is an open-label, dose escalation, multi-center, Phase I/II clinical trial. The purpose of this study is to evaluate an investigational ARTEMIS® ECT204 T-cell therapy in adult patients with GPC3-positive advanced hepatocellular carcinoma (HCC). In this study, a patient's T cells are collected and genetically modified to express Eureka's proprietary anti-GPC3 ARTEMIS T cell receptors (AbTCR). These modified T cells are then reintroduced into the patient to specifically seek out and destroy GPC3-expressing cancer cells. Phase 1 (Dose Escalation Phase): Completed; RP2D of ECT204 was determined. Phase 2 (Expansion Phase): The expansion phase includes 2 study arms. Arm A: Subjects will receive ECT204 as monotherapy Arm B: Subjects will receive pre-treatment with regorafenib (STIVARGA®) before ECT204 administration. The active assessment period of the study will continue for 2 years. Subjects will be followed for assessment of treatment safety and overall survival during Long Term Follow-Up (LTFU; year 2 -15).


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date December 31, 2026
Est. primary completion date December 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically confirmed HCC, which is unresectable, recurrent and/or metastatic. - GPC3-positive expression in HCC tumor cells confirmed by immunohistochemistry (IHC). To be eligible for Phase 2 (expansion phase) of the study, the subject's tumor biopsy sample (resection or needle core sample) must demonstrate that more than 50% of tumor cells exhibit at least 3+ GPC3 expression intensity. - Must have failed, or not tolerated, at least two (2) different anti-HCC systemic agents. - Life expectancy of at least 4 months per the Investigator's opinion. - Karnofsky Performance Scale of 70 or higher. - Measurable disease by RECIST v1.1. Previously treated lesions are allowed as long as there is a new confirmed measurable component. - Child-Pugh score of A6 or better. - Adequate organ function. Exclusion Criteria: - Pre-existing illness (e.g., symptomatic congestive heart failure) that would limit compliance with study requirements. - Active, uncontrolled systemic bacterial, fungal, or viral infection. Subjects with Human Immunodeficiency Virus (HIV), hepatitis B, or hepatitis C are eligible provided their infection is being treated and the viral load is controlled. - Active malignancy (other than HCC), with the exception of cholangiocarcinoma (CCA) or any malignancy without any organ involvement and with an expected survival = 3 years without any treatment (exception: hormone/androgen- deprivation therapy). - Currently receiving or ending (< 14 days from date of consent) liver tumor-directed therapy (e.g., radiation, ablation, embolization), or hepatic surgery. - Concurrently receiving other investigational agents, biological, chemical, or radiation therapies, while participating in the study. - Active autoimmune disease requiring therapy. - Compromised circulation in the main portal vein, hepatic vein, or vena cava due to obstruction. - History of organ transplant. - Advanced HCC involving greater than half (50%) of the liver.

Study Design


Intervention

Biological:
ECT204 T cells
ECT204 is an autologous T-cell therapy whereby a subject's own T cells are transduced with a lentiviral vector expressing the ECT204 transgene.
Drug:
Regorafenib (STIVARGA®, BAY73-4506)
Regorafenib pretreatment before an ECT204 infusion.

Locations

Country Name City State
United States Roswell Park Comprehensive Cancer Center Buffalo New York
United States City of Hope Duarte California
United States Kansas University Medical Center Westwood Kansas

Sponsors (1)

Lead Sponsor Collaborator
Eureka Therapeutics Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To assess the safety and tolerability of ECT204 in adult subjects with advanced HCC The incidence rates of dose limiting toxicities (DLTs) and the type, frequency, and severity of adverse events (AEs) and laboratory abnormalities will be assessed by the number and severity rates after infusion of ECT204. 28 days
Primary To determine the Recommended Phase II Dose (RP2D) of ECT204 (Concluded During Phase 1 of the study) The RP2D was determined by the study Dose Escalation Committee (DEC) and chosen based on the maximum tolerated dose (MTD) that did not exceed the MTD and the maximum administered dose (MAD). The RP2D was also based on the manufacturing capability. 21 months - This outcome was completed on December 20, 2023
Secondary To assess the efficacy of ECT204 in adult subjects with advanced HCC using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (RECIST v1.1) as the primary criterion. The response rate will be assessed by radiographic scans and assessed according to RECIST version 1.1. based upon the following:
Overall Response Rate (ORR), defined as the proportion of subjects with a best overall response (BOR) of either complete response (CR) or partial response (PR).
Disease Control Rate (DCR), defined as the proportion of subjects with BOR of either CR, PR, or stable disease (SD).
Duration of Response (DOR), defined as the time from first response to progressive disease (PD) or death.
Progression-Free Survival (PFS), defined as the time from ECT204 infusion to PD or death.
Overall Survival (OS), defined as the time from ECT204 T-cell infusion to the date of death.
Up to 2 years
Secondary To characterize the pharmacokinetic (PK) profile of ECT204, including the expansion and persistence of ECT204, in our study subject population The peak exposure (Cmax), time to reach peak exposure (Tmax), partial area under the curve (pAUC) and other relevant PK parameters of ECT204 in peripheral blood (PB) will be measured. Up to 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT04209491 - Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
Completed NCT03963206 - Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE) Phase 4
Completed NCT03268499 - TACE Emulsion Versus Suspension Phase 2
Recruiting NCT05263830 - Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
Recruiting NCT05044676 - Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
Recruiting NCT05095519 - Hepatocellular Carcinoma Imaging Using PSMA PET/CT Phase 2
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Completed NCT05068193 - A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers Phase 1
Active, not recruiting NCT03781934 - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations Phase 1/Phase 2
Terminated NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Completed NCT04401800 - Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Phase 2
Withdrawn NCT05418387 - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona N/A
Active, not recruiting NCT04039607 - A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma Phase 3
Terminated NCT03970616 - A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT03642561 - Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE Phase 2/Phase 3
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT03222076 - Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer Phase 2